Patents by Inventor Gerhard Laus

Gerhard Laus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11512068
    Abstract: The invention relates to acid addition salts of ridinilazole and processes for the preparation of ridinilazole using these acid addition salts. In addition, the present invention relates to processes for the preparation of ridinilazole in pure form using acid addition salts of ridinilazole as process intermediates.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: November 29, 2022
    Assignee: Sandoz AG
    Inventors: Erwin Schreiner, Sven Nerdinger, Gerhard Laus
  • Publication number: 20200290995
    Abstract: The invention relates to acid addition salts of ridinilazole and processes for the preparation of ridinilazole using these acid addition salts. In addition, the present invention relates to processes for the preparation of ridinilazole in pure form using acid addition salts of ridinilazole as process intermediates.
    Type: Application
    Filed: July 27, 2018
    Publication date: September 17, 2020
    Applicant: Sandoz AG
    Inventors: Erwin Schreiner, Sven Nerdinger, Gerhard Laus
  • Publication number: 20180237378
    Abstract: The present invention relates to processes, process steps and intermediates useful in the asymmetric bisamidation of malonic ester derivatives wherein the new processes, process steps and intermediates are, for example, useful in the preparation of asymmetric malonic acid bisanilides such as cabozantinib.
    Type: Application
    Filed: August 18, 2016
    Publication date: August 23, 2018
    Applicant: Sandoz AG
    Inventors: Erwin SCHREINER, Sven NERDINGER, Gerhard LAUS
  • Patent number: 8455639
    Abstract: The present invention is directed to a crystalline form of 2-[6-[3(R)-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethyl]-benzonitrile, a process for the preparation of said crystalline form and the use thereof in the manufacture of a pharmaceutical composition.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: June 4, 2013
    Assignee: Sandoz AG
    Inventors: Johannes Ludescher, Josef Wieser, Gerhard Laus
  • Publication number: 20110306764
    Abstract: The present invention is directed to a crystalline form of 2-[6-[3(R)-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethyl]-benzonitrile, a process for the preparation of said crystalline form and the use thereof in the manufacture of a pharmaceutical composition.
    Type: Application
    Filed: December 18, 2009
    Publication date: December 15, 2011
    Applicant: SANDOZ AG
    Inventors: Johannes Ludescher, Josef Wieser, Gerhard Laus
  • Publication number: 20070213389
    Abstract: A method of stimulating endothelial cells cultivated in a nutrient medium to release a growth-factor into the nutrient medium by addition of at least one pentacyclic oxindole alkaloid into the nutrient medium.
    Type: Application
    Filed: May 1, 2007
    Publication date: September 13, 2007
    Inventors: Klaus Keplinger, Martin Wurm, Gerhard Laus
  • Patent number: 7238374
    Abstract: Endothelial cells have the natural property of releasing soluble factors into the fluid surrounding them, said factors altering the behavior of immune cells. In cell systems containing at least endothelial cells, the release of this type of factor, which promotes the proliferation of resting and weakly activated lymphocytes and at the same time inhibits the proliferation of highly activated lymphocytes and transformed lymphoblasts without impairing their other vital functions, is induced by administration of pentacyclic oxindole alkaloids but inhibited by the concurrent administration of tetracyclic oxindole alkaloids.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: July 3, 2007
    Inventors: Klaus Keplinger, Martin Wurm, Gerhard Laus
  • Publication number: 20020039790
    Abstract: Endothelial cells have the natural property of releasing soluble factors into the fluid surrounding them, said factors altering the behavior of immune cells. In cell systems containing at least endothelial cells, the release of this type of factor, which promotes the proliferation of resting and weakly activated lymphocytes and at the same time inhibits the proliferation of highly activated lymphocytes and transformed lymphoblasts without impairing their other vital functions, is induced by administration of pentacyclic oxindole alkaloids but inhibited by the concurrent administration of tetracyclic oxindole alkaloids.
    Type: Application
    Filed: February 20, 2001
    Publication date: April 4, 2002
    Inventors: Klaus Keplinger, Martin Wurm, Gerhard Laus
  • Patent number: 5723625
    Abstract: To produce defined isomer mixtures of compounds with spirocyclic beta-aminocarboxyl and/or beta-aminocarbonyl systems the invention supposes that they be dissolved in solvents which have good dissolving power for these compounds, whose relative permittivity is sufficient to stabilize the amphoteric intermediates occuring in isomerization, which as proton donors constitute hydrogen bridges, whose basicity is less than that of the compounds for isomerization and whose boiling point is so high that an adequate reaction speed can be attained by raising temperature. Further, the invention proposes that the isomerization be prevented, influenced, or terminated by altering at least one of these factors and or by altering the temperature.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: March 3, 1998
    Assignee: Immodal Pharmaka Gesellschaft m.b.H
    Inventors: Dietmar Keplinger, Klaus Keplinger, Gerhard Laus